Panel Discussion: Disrupting Precision Health with Next-generation Proteomics
By bringing essential testing into the home, the COVID-19 pandemic has ushered in a new age in diagnostics and preventative care. While genetic testing is generally the most widely recognized, fulfilling the true promise for precision health lies in the power of the protein biomarker to see and detect disease at its earliest stages. In this panel discussion, healthcare visionary, Powering Precision Health Founder and CEO of Quanterix, Kevin Hrusovsky, and panelists will explore the potential to harness ultra-sensitive protein quantitation to deliver non-invasive blood testing solutions for homecare use, such as those reliant on a capillary (finger prick) sample or dried blood swab rather than a traditional blood draw. Beginning with COVID-19, and expanding into other critical disease categories, including oncology and neurology, these regular blood-based biomarker screenings have the potential to aid in disease prevention, study critical research questions (i.e., immunity and treatment response), and lower healthcare costs through early intervention. Hrusovsky and his panelists will also share early efforts to realize this vision through COVID-19 serosurveillance efforts with some of the world’s largest payor groups and discuss how this is laying the groundwork for a disruption in medicine that will re-shape the diagnostics industry.
Moderator: Kevin Hrusovsky, MBA, President, Chairman, Chief Executive Officer, Quanterix Panelists:
Panelists: Kevin Knopp, PhD, Co-founder and Chief Executive Officer, 908 Devices Inc; Tatiana Plavina, PhD, Head, Bioanalytical Sciences and Neuro Biomarkers; Clinical Biomarker Innovation and Development, Takeda; Charlotte Teunissen, PhD, Professor, Neurochemistry, UMS Amsterdam
Share this page